EBOS Group Limited

EBO

NZEBOE0001S6

Pharmaceuticals

End-of-day quote New Zealand S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
34.1 ^NZD	-0.29%		+3.81%	-3.94%

16/07	EBOS Group to Not Participate in Prime100 Potential Sale	MT
03/07	New Zealand Shares Flat on US Rate Cut Hopes; Ebos Boosts MedAdvisor Stake	MT

EBOS Group Limited Announces Change of Australian Registered Office

January 17, 2017 at 06:28 am IST

EBOS Group Limited announced that its Australian registered office details have changed. EBOS Group's new registered office in Australia is located at: Level 7, 737 Bourke Street, Docklands, Victoria 3008.

Latest news about EBOS Group Limited

EBOS Group to Not Participate in Prime100 Potential Sale	16/07	MT
New Zealand Shares Flat on US Rate Cut Hopes; Ebos Boosts MedAdvisor Stake	03/07	MT
Ebos Boosts MedAdvisor Stake; Says No Plan for Change of Control Proposal	03/07	MT
MedAdvisor Limited announced that it has received funding from EBOS Group Limited	03/07	CI
New Zealand shares fall as hopes of early Fed rate cut fade; Australia closed	10/06	RE
Jarden Securities Upgrades Ebos Group to Overweight from Neutral, Price Target is NZ$38.00	29/04	MT
New Zealand Shares Drop on Consumer Pessimism; Ebos Group Falls 3% After Appointing New CFO	26/04	MT
Ebos Group Appoints New CFO	26/04	MT
EBOS Group Limited Announces Chief Financial Officer Changes	26/04	CI
Evans & Partners Starts Ebos Group at Positive, Price Target is NZ$40.94	24/04	MT
Ebos Group Declares DRP Strike Price for Interim Dividend	13/03	MT
Morgan Stanley Adjusts EBOS Group’s Price Target to AU$37 From AU$38, Keeps at Overweight	06/03	MT
Morgan Stanley Adjusts EBOS’ Price Target to NZ$39.20 From NZ$41.05, Keeps at Overweight	06/03	MT
EBOS Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023	21/02	CI
EBOS Group Limited to Seek M&A	21/02	CI
Transcript : EBOS Group Limited, H1 2024 Earnings Call, Feb 21, 2024	21/02
EBOS Posts 7% Rise in Half Year FY24 Revenue, EPS Up 6.6%	21/02	MT
Correction: --EBOS Posts Half Year FY24 Revenue Up 7% to AU$6.58 Billion; Underlying EPS of AU$0.795	21/02	MT
EBOS Posts Half Year FY24 Revenue Up 7% to AU$6.58 Million; Underlying EPS of AU$0.795	21/02	MT
EBOS Group Limited Announces Interim Dividend of the Year Ending June 30, 2024, Payable 22 March 2024	21/02	CI
New Zealand shares post biggest weekly jump since Nov; Australia closed	26/01	RE
New Zealand shares snap 4-day rally but set for weekly gain; Australia closed	26/01	RE
New Zealand Shares Rise on Tuesday on Upbeat Economic Data; EBOS Raises Ownership in Transmedic to 90%	19/12	MT
EBOS Group Raises Transmedic Stake to 90% from 51%	19/12	MT
EBOS Group Limited acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million.	19/12	CI

Chart EBOS Group Limited

Duration

Period

More charts

Company Profile

EBOS Group Limited is a marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is a marketer and distributor of animal care brands. Its segments include Healthcare, Animal Care, and Corporate. The Healthcare segment includes sales of healthcare products in a range of sectors, own brands, retail healthcare, pharmacy, hospital and logistic services, and wholesale activities. The Animal Care segment includes sales of animal care products in a range of sectors, own manufactured and contract manufactured brands, retail, and wholesale activities. It sources and supplies a range of surgical, medical, and pharmaceutical products. Its Community Pharmacy business includes Symbion, ProPharma, Pharmacy Wholesalers Russells, TerryWhite Chemmart, Good Price Pharmacy Warehouse, healthSAVE, Ventura Health, Minfos, DoseAid, Intellipharm, Endeavour Consumer Health, and Red Seal. Its contract logistics include Healthcare Logistics and Clinect.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for EBOS Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

34.1 NZD

Average target price

38.21 NZD

Spread / Average Target

+12.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
EBOS GROUP LIMITED	-3.94%	400.18Cr
MCKESSON CORPORATION	+25.72%	7.55TCr
CARDINAL HEALTH, INC.	-4.79%	2.34TCr
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+17.81%	895.71Cr
HUADONG MEDICINE CO., LTD	-31.67%	682.85Cr
H. LUNDBECK A/S	+22.22%	559.17Cr
GALENICA AG	+3.85%	426.48Cr
MEDIPAL HOLDINGS CORPORATION	+13.98%	348.55Cr
CHINA NATIONAL MEDICINES CORPORATION LTD.	+10.59%	328.88Cr
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-14.43%	314.55Cr

Pharmaceuticals Wholesale